Furthermore, key risk factors for NAFLD, including insulin insensitivity, obesity, and dyslipidemia, are alleviated by FGF-21, and FGF-21 has been reported to reverse liver steatosis while counteracting obesity and enhancing insulin sensitivity [20]. Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.